delug updat pre-releas last week publish updat
model pt sever compani includ
reflect recent announc well minor cadenc adjust
buy consensu ep forecast map scatter
high respons question break-out session last week indic
good place given outsiz fx headwind
 time dynam associ order come strong
full-year note right on-track initi expect tailwind
slightli lower resin cost deferr januari tariff increas off-set slightli
less favor fx rel embed guidanc trim
ep forecast though ep forecast
buy pt rais pt higher out-
point rev beat test volum beat
note q/q volum increas test largest sequenti jump to-dat
cologuard coincid start co-promot oct ad
new order doc big jump prior run-rat suggest new
rep account new doc add right gate feedback
convers management last week suggest integr rep
smooth bottom line think beat squar address one main
question around stock impact look ahead given outsiz
upsid think guidanc bogey least prior bull case
rev vs initi guidanc alreadi look realist
piec fall place capit massiv screen market
us continu see room upsid expect reiter buy rate
hold updat model account better-than-expect
revenu pre-releas last week expect vs prior guid
driven strength licens technolog y/i ex-labcorp mdx
segment y/i ex-lh also issu initi revenu guidanc
line estimate bracket consensu includ
contribut mil flow cytometri acquisit
hold pt updat model account two
small acquisit corebiom novosani expect add
rev modestli dilut ep separ trim
pt base reduc multipl dnag/molecular collect
segment rev sotp follow somewhat cautiou commentari
last week player consum genom ecosystem labcorp note
pace growth consum genet busi could slower given dtc test demand
larg driven market discount seem rel
prior year initi revenu guidanc assum low-singl digit growth
array stem cautiou nt outlook consum busi
becton dickinson co
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
rev test
rev test
realiz
test annual us screen oppti
valu futur pipelin test
price impli equiti valu
rev discount back
test earli detect colorect cancer offer
viabl altern exist screen techniqu
colonoscopi fit/fobt signific potenti
drastic improv complianc becom gold
cologuard address market alon
in-network w/ us pvt payor
premium asp expand label
share us average risk pop
expand label age group
acceler penetr co-promot
success execut sale forc lab capac
label indic use high-risk patient
penetr larg health system
npv pipelin
higher expect oper expens support
emerg competit threat blood-bas
test liquid biopsi innov
dilut financ fund pipelin
ceo/cfo key leadership departur
slower ramp co-promot
page
pleas see import disclosur inform page report
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor total net product incom expens dividend share share analysisgross research sg ebitda oper incom net growth analysisnet incom healthcar
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor net product expens share share analysisgross base analysisnet healthcar
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor net product amortz incom expens share share dilut analysi non-gaap gross research sg ebitda depreci amortz oper incom net growth analysisnet incom dilut healthcar
histor project quarterli incom statement
million except per share data
page
pleas see import disclosur inform page report
histor net product administr expens share share ep analysiscorpor gross gross administr analysisnet administr healthcar
becton dickinson co
becton dickinson co global medic technolog compani manufactur sell broad rang medic suppli devic
laboratori equip diagnost product compani oper two busi divis medic life scienc diagnost
lead develop manufactur divers line oral fluid diagnost product specimen collect
devic use variou in-vitro diagnost test applic ivd product focus convert tradit diagnost modal
central test locat hospit clinic lab rapid point-of-car set physician offic home uniqu oral
subsidiari dna genotek focus provid high-qual biolog sampl collect product end-to-end servic human
genom microbiom infecti diseas applic oragene-dx oracollect-dx product line first fda
clear saliva-bas dna collect devic in-vitro diagnost use
molecular diagnost compani focus develop commerci non-invas test earli detect
cancer first flagship product cologuard fda-approv screen test earli detect colorect cancer pre-cancer
develop manufactur sell product detect presenc certain biochem protein nucleic acid sampl base
proprietari xmap technolog xmap technolog enabl research laboratori biomed research field perform
bioassay identifi new gene discov develop new drug diagnos genet pathogen-rel diseas monitor guid
becton dickinson co
pt reflect horizon dcf impli ev ebitda ep risk util new product uptak
pt base sotp model impli ev rev risk slower consum genom demand ou hiv self-test ramp
pt repres horizon dcf impli rev discount back risk pipelin execut sale forc
pt repres horizon dcf impli ev ebitda rev risk mdx pipelin execut competit
brandon couillard certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
matthew stanton certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
michael koban certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
page
pleas see import disclosur inform page report
